跳转至内容
Merck
CN

Neuroleptic malignant syndrome induced by lamotrigine.

Clinical neuropharmacology (2013-06-21)
Masamichi Ishioka, Norio Yasui-Furukori, Kojiro Hashimoto, Norio Sugawara
摘要

This case report describes a 54-year-old man with bipolar I disorder who was treated with aripiprazole (ARP) and lithium. The patient was admitted to our hospital because of aggravation of depressive symptoms, and treatment with lamotrigine (LTG) was initiated. Two weeks after admission, we discontinued administration of ARP after the appearance of a tremor. Three weeks after discontinuing ARP, the patient developed a high fever, rigidity of the arms, diarrhea, dysphagia, and diaphoresis. We suspected these symptoms were consistent with neuroleptic malignant syndrome and therefore removed the application of LTG. After 2 days, most of the patient's symptoms and blood results had improved, leading us to conclude that the LTG treatment had induced neuroleptic malignant syndrome. Thus, the purpose of this case report was to warn psychiatrists against therapy with LTG, as it may be conducive to neuroleptic malignant syndrome.

材料
产品编号
品牌
产品描述

Supelco
拉莫三嗪, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
拉莫三嗪, ≥98%, powder
Supelco
Lamotrigine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
USP
拉莫三嗪, United States Pharmacopeia (USP) Reference Standard
拉莫三嗪, European Pharmacopoeia (EP) Reference Standard
拉莫三嗪, European Pharmacopoeia (EP) Reference Standard
峰鉴别用拉莫三嗪, European Pharmacopoeia (EP) Reference Standard